Norepinephrine: From a Peripheral Sympathetic Neurotransmitter and Central State Regulator to Support for Vasopressor Therapy in Critical Care

Introduction

 

Norepinephrine is a core molecule that appears across neuroscience, pharmacology, and critical care medicine. In the periphery, it serves as an important chemical signal in the sympathetic nervous system and participates in the maintenance of vascular tone and perfusion pressure. In the central nervous system, it is closely related to arousal, attention, cognition, stress responses, and sleep-state transitions. Clinically, it is also a first-line vasopressor in severe acute hypotension and septic shock. To understand norepinephrine, it is first necessary to distinguish its different roles in peripheral regulation, intracerebral signaling, and clinical vasopressor support.

 

1. What Is Norepinephrine

 

Norepinephrine, also written as noradrenaline, is a catecholamine molecule. It belongs to the same catecholamine family as epinephrine and dopamine. Norepinephrine is both an important neurotransmitter in the peripheral sympathetic nervous system and an important neuromodulator in the central nervous system. In the periphery, it participates in the regulation of vascular tone and stress responses; in the brain, it is involved in the regulation of arousal, attention, cognition, and stress responses.

 

In the brain, the locus coeruleus is one of the principal sources of the norepinephrine system, sending widespread projections to multiple regions including the cerebral cortex, hippocampus, amygdala, and hypothalamus. Norepinephrine therefore contributes to whole-brain state regulation such as arousal, attention, stress, and sleep-state transitions. In the periphery, most postganglionic sympathetic fibers use norepinephrine as their main transmitter, whereas the postganglionic sympathetic fibers innervating sweat glands are cholinergic and primarily release acetylcholine.

 

2. Synthesis, Release, and Clearance of Norepinephrine in the Body

 

2.1 Biosynthesis

Norepinephrine is a catecholamine. Its biosynthesis begins with tyrosine. Tyrosine is converted to L-DOPA by tyrosine hydroxylase, and L-DOPA is then converted to dopamine by aromatic L-amino acid decarboxylase. After dopamine enters storage vesicles, it is converted to norepinephrine by dopamine beta-hydroxylase. In cells that express phenylethanolamine N-methyltransferase, norepinephrine can be further converted into epinephrine.

 

2.2 Peripheral Release and Actions

In the periphery, norepinephrine is released mainly from postganglionic sympathetic nerve terminals and may also be secreted in part by the adrenal medulla. Once released, norepinephrine binds to adrenergic receptors on target organs and participates in vasoconstriction, regulation of cardiac activity, and regulation of smooth muscle function. In the circulatory system, norepinephrine is closely related to the maintenance of vascular tone and the regulation of perfusion pressure.

 

2.3 Intracerebral Sources and Projections

In the central nervous system, the locus coeruleus is one of the principal sources of norepinephrine-producing neurons in the brain. In addition to the locus coeruleus, other noradrenergic nuclei in the pons and medulla also contribute to norepinephrine signaling in the brain. Neurons associated with the locus coeruleus project to multiple regions including the cerebral cortex, hippocampus, amygdala, and hypothalamus. Norepinephrine therefore participates in the regulation of brain functions such as arousal, attention, stress responses, cognitive activity, and sleep-state transitions.

 

2.4 Reuptake and Metabolism

After norepinephrine is released, termination of its action depends primarily on reuptake. Norepinephrine can be taken back up into presynaptic nerve terminals through the norepinephrine transporter and then enters subsequent metabolic pathways. The metabolism of norepinephrine involves enzymes such as monoamine oxidase and catechol-O-methyltransferase and can generate multiple metabolites. Many drugs that act on the norepinephrine system target reuptake, receptor binding, or metabolic processes.

 

3. Major Functions of Norepinephrine in the Brain

 

3.1 Overview of Its Major Central Functions

 

Functional Domain	Main Issues Involved
Arousal and vigilance	Maintenance of wakefulness, environmental monitoring, response readiness
Attentional regulation	Sustained attention, information filtering, stimulus responsiveness
Cognition and emotional stress	Working memory, learning, stress responses
Sleep-state transitions	Shifts between wakefulness and sleep

 

3.2 Arousal, Vigilance, and Attentional Regulation

Norepinephrine participates in the maintenance of wakefulness and also influences how the brain monitors external stimuli and prepares responses. When norepinephrine release levels and the firing patterns of the locus coeruleus change, sustained attention, information filtering, and responsiveness to unexpected stimuli also change accordingly.

 

3.3 Cognitive Activity and Emotional Stress

Norepinephrine is involved in working memory, learning, and the processing of emotion-related information. Under stress, activity in the locus coeruleus-norepinephrine system changes, as reflected by altered firing of norepinephrine neurons and altered norepinephrine release. It is therefore frequently studied in the context of stress responses and emotional regulation.

 

3.4 Sleep and State Transitions

Norepinephrine participates in transitions between wakefulness and sleep. During wakefulness, activity in the locus coeruleus-norepinephrine system is relatively high. After sleep begins, the activity pattern of this system changes, and activity declines markedly during rapid eye movement (rapid eye movement, REM) sleep. Norepinephrine is therefore commonly studied in relation to sleep architecture and sleep-wake transitions.

 

4. Four Major Directions in Frontier Research on Norepinephrine

 

In recent norepinephrine-related research, areas receiving increasing attention have expanded beyond simple changes in overall levels to include firing patterns, sleep-related neuroimmune interactions, brain fluid dynamics during sleep, and human-derived locus coeruleus norepinephrine neuron models. Among these advances, some conclusions are derived mainly from animal experiments or human in vitro models, pointing to new mechanistic directions that still require further validation and linkage to human physiology and disease states.

 

Research Direction	Main Research Question	What This Type of Research Indicates
Firing patterns of the locus coeruleus-norepinephrine system and brain networks	Comparing how tonic-like activity and burst-like activity alter the dynamics of norepinephrine release and drive different brain network states	This suggests that the function of the norepinephrine system is related not only to whether its level is high or low, but also closely to firing pattern and network state. At present, such conclusions are derived mainly from animal experiments and are particularly valuable for mechanistic interpretation.
Microglia-norepinephrine interactions during sleep	Investigating how microglia influence sleep and norepinephrine transmission through calcium signaling and P2Y12-Gi-related mechanisms	This indicates that norepinephrine research has extended into sleep regulation and neuroimmune interactions. At this stage, the relevant mechanistic evidence comes mainly from mouse studies and is well suited for understanding regulatory pathways.
Vasomotion and glymphatic clearance during non-rapid eye movement sleep	Investigating how fluctuations in norepinephrine drive slow vasomotion and how this relates to cerebrospinal fluid flow and glymphatic clearance	This suggests that, in addition to influencing neural activity, norepinephrine may also participate in the regulation of brain fluid dynamics during sleep. Current evidence in this area is based mainly on animal studies and is used primarily to propose new physiological mechanistic insights.
Human pluripotent stem cell-derived locus coeruleus norepinephrine neuron models	Establishing methods to generate human locus coeruleus norepinephrine neurons for disease modeling and drug research	This indicates that norepinephrine research now has in vitro models that are closer to human systems, which is helpful for disease modeling and drug screening. However, these results belong to human cell model research and still cannot be directly equated with in vivo physiology or clinical manifestations.

 

5. Clinical Positioning and Key Points in the Use of Norepinephrine for Vasopressor Support in Critical Care

 

5.1 Indications in the Prescribing Information

Norepinephrine injection is used to raise blood pressure in adults with severe acute hypotension. The clinical goal is to restore and maintain the blood pressure required for organ perfusion.

 

5.2 Clinical Positioning in Septic Shock

The 2026 international guidelines for adult sepsis and septic shock list norepinephrine as a first-line vasopressor for septic shock, recommending it over dopamine, epinephrine, and selepressin, and also suggesting it over vasopressin or angiotensin II. For patients whose norepinephrine dose continues to rise while mean arterial pressure still fails to reach the target, the guidelines recommend adding vasopressin. If mean arterial pressure remains insufficient after combining norepinephrine and vasopressin, epinephrine is then considered. For patients with septic shock complicated by cardiac dysfunction, the guidelines state that either norepinephrine or epinephrine may be used as first-line vasopressor therapy, with further judgment based on heart rate, cardiac rhythm, and perfusion status.

 

5.3 Characteristics of Its Vasopressor Effect

Norepinephrine raises perfusion pressure by enhancing vasoconstriction and increasing peripheral vascular resistance. In distributive shock, especially septic shock, this action is well aligned with the therapeutic goals of hemodynamic support in critical care, which is why it is placed in the first-line position.

 

5.4 Main Precautions During Use

Before using norepinephrine, hypovolemia should be addressed first. During administration, a large vein should be selected whenever possible and the infusion site should be monitored continuously, with vigilance for local tissue injury caused by extravasation. In situations such as septic shock where perfusion pressure needs to be restored promptly, initiation of vasopressor therapy should not be delayed while waiting for central venous catheter placement. However, after starting through a peripheral vein, the infusion route and local reactions must still be monitored closely.

 

6. Distinguishing Different Norepinephrine-Related Entities and Their Uses

 

The table below distinguishes four categories of entities: norepinephrine itself, clinical formulations, drugs acting on the norepinephrine system, and diagnostic or research tools.

 

Category	Main Use	Typical Examples	Nature of the Entity
Norepinephrine itself	Explaining sympathetic neurotransmission, arousal in the brain, and stress regulation	Peripheral sympathetic transmitter, locus coeruleus norepinephrine system	Norepinephrine itself
Clinical formulations	Vasopressor support	Norepinephrine bitartrate injection, premixed injection	Dosage forms of norepinephrine
Drugs acting on the norepinephrine system	Regulating reuptake, receptors, or system activity	Atomoxetine, venlafaxine	Drugs that regulate the norepinephrine system
Diagnostic and research tools	Used for diagnosis, mechanistic research, and model construction	Catecholamine testing, locus coeruleus-norepinephrine imaging, human locus coeruleus norepinephrine neuron models	Tools used to detect or study norepinephrine

 

7. Product Navigation Table for Norepinephrine Precursors, Metabolism, Hemodynamics, and Central Pharmacology (Choose Tables 1–4 by Research or Experimental Goal)

 

Research or Experimental Goal	Recommended Table to Read First	Why Start with This Table	Recommended Table(s) to Read Alongside	Why Read Them Together
Want to first build a basic framework for norepinephrine research and distinguish which compounds are precursors, which are the parent compound itself, and which serve as clinical formulation references	Table 1	Table 1 places tyrosine, L-DOPA, dopamine, norepinephrine, epinephrine, and norepinephrine bitartrate on the same main line, making it easier to first clarify the basic hierarchy from biosynthesis to exogenous administration	Table 2	After understanding the precursors and the parent compound, Table 2 helps connect terminal metabolites, methylated products, and detection indicators to form a complete pathway-level understanding
Already have cells, tissues, or animal samples on hand and want to determine whether changes in norepinephrine mainly arise from altered synthesis, altered release, or altered metabolic turnover	Table 1	Table 1 first addresses the question of “where does the source come from,” making it suitable for first examining the relationships among precursor supplementation, direct precursors, and the parent compound, and for judging whether the issue lies in upstream supply or in the level of the parent compound itself	Table 2	Table 2 further helps distinguish whether the change lies in methylation, deamination, or terminal metabolism, making it easier to map detection results onto specific metabolic steps
Want to construct a catecholamine metabolic profile or plasma/urine detection panel and distinguish which molecules are suitable for inclusion	Table 2	Table 2 focuses on metabolites and detection references for norepinephrine and related catecholamines, making it suitable for first establishing a framework for deciding what to measure and how to interpret them together	Table 1	After the detection panel is defined, going back to Table 1 helps map each metabolite back to its precursor, parent compound, and parallel catecholamines, avoiding interpretation based only on metabolites without considering their source
Want to study blood pressure, vasoconstriction, peripheral receptor blockade, or vasopressor pharmacology, and compare norepinephrine with other hemodynamic regulators	Table 3	Table 3 concentrates on peripheral vasopressor agents, receptor blockers, and synthesis inhibitors, making it suitable for first separating experimental routes such as “enhancing vascular tone,” “blocking receptor responses,” and “reducing endogenous synthesis”	Table 1	After the peripheral pharmacology framework is clarified, returning to Table 1 helps relate exogenous vasopressor agents back to endogenous norepinephrine, its parent precursor framework, and formulation references
Want to distinguish whether “reduced endogenous norepinephrine” and “insufficient blood pressure response to exogenous administration” are actually the same issue	Table 1	Table 1 places the parent compound, precursors, and clinical formulation references together, making it easier to first distinguish whether the research question concerns insufficient endogenous production or issues related to exogenous supplementation and formulation conditions	Table 3	Table 3 then helps further determine whether receptor sensitivity, peripheral vascular responsiveness, or antagonistic factors are involved, avoiding the assumption that all low responses are simply caused by low norepinephrine levels
Want to study the locus coeruleus-norepinephrine pathway, central sympathetic inhibition, attentional control, or sedation-related pharmacology	Table 4	Table 4 focuses on drugs that regulate the norepinephrine system and central pharmacological tools, making it suitable for first distinguishing among regulatory modes such as reuptake inhibition, receptor agonism, and active metabolites	Table 1	After first clarifying the mode of regulation, returning to Table 1 helps map these central pharmacological changes back to norepinephrine itself and its upstream precursors, rather than mistaking system-regulating drugs for substitutes for the parent compound
Want to compare where drugs such as venlafaxine, desvenlafaxine, viloxazine, clonidine, guanfacine, and dexmedetomidine act within the norepinephrine system	Table 4	Table 4 groups reuptake inhibitors and central receptor agonists together by pharmacological action, making it suitable for first distinguishing whether they affect transporters, prefrontal regulation, or suppression of central sympathetic output	Tables 1 and 2	Reading Table 1 alongside helps distinguish these drugs from norepinephrine itself, while reading Table 2 alongside helps judge which metabolic indicators these regulatory effects may eventually be reflected in
Want to design a relatively complete norepinephrine research plan from “pathway starting point to functional output,” rather than measuring only a single indicator	Table 1	Table 1 first establishes the main line, making it easier to determine whether the entry point should be precursor supplementation, parent-compound administration, or comparison with parallel catecholamines	Tables 2, 3, and 4	Table 2 fills in metabolic readouts, Table 3 fills in peripheral hemodynamics and receptor pharmacology, and Table 4 fills in central regulation and system pharmacology. Reading the three tables together makes it easier to form a complete experimental framework
Want to perform experiments on catecholamine excess, receptor blockade, or pharmacological reversal, and observe how norepinephrine responses change under blocking conditions	Table 3	The synthesis inhibitors, receptor blockers, and peripheral vasopressor agents in Table 3 can be used to build experimental designs such as “suppress before enhancement” or “antagonize after administration”	Table 2	Reading Table 2 alongside then helps align pharmacological responses with metabolic results, allowing judgment as to whether the change mainly occurs at the receptor level or has already propagated to the level of metabolic turnover
Want to infer experimental status from detection results, for example, when certain metabolites are elevated, and determine whether to first suspect precursor supplementation, increased release, or accelerated metabolism	Table 2	Table 2 first provides an observation entry point at the metabolite level, making it suitable for reverse inference starting from sample results	Tables 1 and 3	Reading Table 1 alongside allows tracing back to precursor and parent-compound sources, while Table 3 helps analyze whether the response arises from release, blockade, or hemodynamic intervention in combination with peripheral pharmacology or receptor conditions

 

Table 1 | Precursors in the Catecholamine Pathway, Core Parent Compounds, and Formulation References

 

Category	CAS No.	Aladdin Catalog No.	Name	Specification or Purity	Product Features and Applications
Starting precursor for catecholamine synthesis	60-18-4	T1521620	L-Tyrosine	Animal origin-free, ≥99%, fermentation-derived	The starting precursor in catecholamine biosynthesis, used for precursor supplementation, cell culture, or metabolic pathway intervention experiments to observe changes in downstream dopamine, norepinephrine, and epinephrine levels.
Upstream precursor of norepinephrine	59-92-7	D111048	L-dopa	Moligand™, ≥99%	Used to build a comparative synthesis chain of tyrosine to DOPA to dopamine to norepinephrine, and to observe how decarboxylation and subsequent hydroxylation steps affect norepinephrine production.
Direct precursor of norepinephrine	51-61-6	A303863	4-(2-Aminoethyl)benzene-1,2-diol	Moligand™, ≥98%	As the direct precursor of norepinephrine, it is used to compare dopamine and norepinephrine in receptor actions, hemodynamic responses, and oxidative stress, and can also serve as an analytical standard.
Core catecholamine parent compound	51-41-2	N109573	L-Noradrenaline	Moligand™, ≥98%	Used to establish experimental models centered on norepinephrine itself for receptor studies, vasoconstriction, cellular stress, and metabolic turnover, and can also serve as a reference standard for liquid chromatography and mass spectrometry detection.
Parallel catecholamine parent compound	51-43-4	E113174	L-Adrenaline	Moligand™, ≥98%	Used to compare norepinephrine with epinephrine in peripheral vasopressor effects, cardiac responses, and receptor spectrum differences, and is commonly used in catecholamine pharmacology and hemodynamic comparison experiments.
Norepinephrine precursor drug	23651-95-8	D129407	Droxidopa（L-DOPS）	Moligand™, ≥98%	As a precursor drug for norepinephrine, it is used in precursor supplementation strategies, decarboxylation conversion, and pharmacological studies related to neurogenic hypotension, and can also be used to observe changes in norepinephrine levels after exogenous supplementation.
Clinical vasopressor formulation reference	69815-49-2	N301475	L-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol bitartrate	≥98%	Used in studies of norepinephrine formulations, dosage forms, and solution stability, and can also serve as a formulation reference in hemodynamic support and clinical vasopressor condition design.

 

Table 2 | Norepinephrine-Related Catecholamine Metabolites and Detection References

 

Category	CAS No.	Aladdin Catalog No.	Name	Specification or Purity	Product Features and Applications
Norepinephrine metabolite	534-82-7	M1369229	3-Methoxy-4-hydroxyphenylglycol(HMPG)	Moligand™,≥95%	An important product in the norepinephrine metabolic pathway, used to evaluate the strength of central or peripheral norepinephrine turnover, and can also serve as a quantitative reference for biological sample analysis.
Terminal catecholamine metabolite	55-10-7	H113502	DL-4-Hydroxy-3-methoxymandelic acid	Moligand™, ≥98%	Used in studies of terminal catecholamine metabolism and body-fluid detection, and commonly used in assessing the metabolic load of norepinephrine and epinephrine.
Methylated epinephrine metabolite	5001-33-2	M611804	Metanephrine	Moligand™, ≥98%	Used in catecholamine metabolic profiling and body-fluid detection related to tumors, and can be combined with norepinephrine and its metabolites to build a detection panel.
Methylated norepinephrine metabolite	97-31-4	N612364	Normetanephrine	Moligand™, ≥94%	A key indicator in norepinephrine metabolic testing, used for analysis of norepinephrine metabolic status in plasma, urine, and tissue samples.
Terminal dopamine metabolite	306-08-1	H156999	4-Hydroxy-3-methoxyphenylacetic Acid（HVA）	≥98%(HPLC)	Used in dopamine metabolism studies and overall catecholamine metabolic profiling, and can help distinguish situations dominated by dopamine turnover from those accompanied by abnormal norepinephrine changes.
Methylated dopamine metabolite	1477-68-5	M419970	3-Methoxytyramine hydrochloride(3-MT)	≥98%	Used in studies of methylated dopamine metabolism, and can also be incorporated into catecholamine-related detection panels for joint interpretation together with norepinephrine metabolites.
Deaminated norepinephrine metabolite	28822-73-3	R135061	DL-3,4-Dihydroxyphenylglycol	≥95%	As an early norepinephrine metabolite, it is used in studies of deamination after norepinephrine release, nerve-terminal turnover, and segmented analysis of the metabolic pathway.

 

Table 3 | Hemodynamic Regulators, Receptor Pharmacology, and Synthesis Inhibitors

 

Category	CAS No.	Aladdin Catalog No.	Name	Specification or Purity	Product Features and Applications
Peripheral vasopressor reference compound	59-42-7	S161304	L-Phenylephrine	Moligand™, ≥98%(HPLC)	Used to establish a vasopressor reference centered primarily on peripheral vasoconstriction and to compare differences between norepinephrine and pure peripheral receptor agonist conditions in blood pressure and vascular responses.
Catecholamine synthesis inhibitor	672-87-7	M107878	α-Methyl-L-tyrosine	Moligand™, ≥98%	A tyrosine hydroxylase inhibitor used to reduce catecholamine synthesis, interfere with norepinephrine reserves, and analyze the contribution of endogenous norepinephrine to behavior or hemodynamic responses.
α-Receptor blocker	59-96-1	P612794	phenoxybenzamine	Moligand™	Used in studies of catecholamine excess states and α-receptor blockade, and can be used to observe changes in norepinephrine-induced vasoconstrictive responses before and after receptor blockade.
Peripheral vasopressor agent	43218-56-0	M413320	Midodrine hydrochloride	≥98%	Used in studies of peripheral α-receptor-mediated vasoconstriction and neurogenic hypotension, and can serve as a comparison with intravenous norepinephrine under different administration-route conditions.
α-Receptor antagonist	73-05-2	P133574	Phentolamine Hydrochloride	≥98%	Used in studies of α-receptor antagonism and reversal of norepinephrine vascular effects, and can also serve as a pharmacological reference for the management of norepinephrine extravasation and local ischemic intervention.

 

Table 4 | Drugs Regulating the Norepinephrine System and Central Pharmacological Tools

 

Category	CAS No.	Aladdin Catalog No.	Name	Specification or Purity	Product Features and Applications
Stereoisomer control for monoamine transporter studies	96847-55-1	L611511	Dextromilnacipran	Moligand™,≥98%	Used in studies of monoamine transporter pharmacology, differences in stereoisomer actions, and mechanisms of norepinephrine reuptake inhibition.
Serotonin/norepinephrine reuptake inhibitor	93413-69-5	D337434	D,L-Venlafaxine	Moligand™, ≥98%	Used in studies of monoamine reuptake inhibition and in observing how the joint regulation of norepinephrine and serotonin affects emotion, pain perception, and autonomic indicators.
Central α2 receptor agonist	145108-58-3	D129813	Dexmedetomidine HCl	Moligand™, ≥98%	Used in studies of inhibition of the locus coeruleus-norepinephrine pathway, sedation, and sympathetic suppression, and can also be used to observe the decrease in norepinephrine release following activation of central α2 receptors.
Central α2A receptor agonist	29110-48-3	G133358	Guanfacine hydrochloride	≥98%(HPLC)	Used in studies of prefrontal cortical function, attentional control, and central α2A receptor regulation, and can serve as a reference for norepinephrine signaling regulation.
Drug regulating the norepinephrine system	35604-67-2	R341328	Viloxazine hydrochloride	≥98%	Used in studies of attentional function and regulation of the norepinephrine system. Available data suggest that its action is related to inhibition of norepinephrine reuptake, but its exact mechanism in ADHD has not yet been fully clarified.
Active metabolite of venlafaxine	386750-22-7	D276264	Desvenlafaxine succinate monohydrate	≥98%	Used in studies of monoamine reuptake regulation and can be compared with venlafaxine to examine the effects of the parent compound and its active metabolite on the norepinephrine system.
Central α2 receptor agonist	4205-91-8	C102161	Clonidine hydrochloride	≥98%	Used in studies of central α2 receptor agonism, suppression of sympathetic output, and negative-feedback regulation of norepinephrine release, and is also commonly used in autonomic regulation experiments.
Norepinephrine reuptake inhibitor	82248-59-7	A129721	Atomoxetine HCl	≥98%	Used in studies of norepinephrine system regulation and attentional function, and can serve as a relatively selective pharmacological tool for inhibition of the norepinephrine transporter. It is suitable for comparative use with dual-pathway monoamine-modulating drugs.

 

Note: The above are representative Aladdin products. For more product specifications, please search the Aladdin official website using the product name/CAS/catalog number.

 

References

 

[1] BERRIDGE C W, WATERHOUSE B D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes[J]. Brain Research Reviews, 2003, 42(1): 33-84. DOI:10.1016/S0165-0173(03)00143-7.

 

[2] SCHWARZ L A, LUO L. Organization of the locus coeruleus-norepinephrine system[J]. Current Biology, 2015, 25(21): R1051-R1056. DOI:10.1016/j.cub.2015.09.039.

 

[3] GRIMM C, DUSS S N, PRIVITERA M, et al. Tonic and burst-like locus coeruleus stimulation distinctly shift network activity across the cortical hierarchy[J]. Nature Neuroscience, 2024, 27(11): 2167-2177. DOI:10.1038/s41593-024-01755-8.

 

[4] MA C, LI B, SILVERMAN D, et al. Microglia regulate sleep through calcium-dependent modulation of norepinephrine transmission[J]. Nature Neuroscience, 2024, 27(2): 249-258. DOI:10.1038/s41593-023-01548-5.

 

[5] HAUGLUND N L, ANDERSEN M, TOKARSKA K, et al. Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep[J]. Cell, 2025, 188(3): 606-622.e17. DOI:10.1016/j.cell.2024.11.027.

 

[6] TONG C, LI W, ZOU Y, et al. Norepinephrine-mediated arousal fluctuations drive inverted U-shaped functional connectivity dynamics[J]. Nature Communications, 2025, 16: 11318. DOI:10.1038/s41467-025-66436-x.

 

[7] TAO Y, LI X, DONG Q, et al. Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells[J]. Nature Biotechnology, 2024, 42(9): 1404-1416. DOI:10.1038/s41587-023-01977-4.

 

[8] PRESCOTT H C, ANTONELLI M, ALHAZZANI W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026[J]. Intensive Care Medicine, 2026. DOI:10.1007/s00134-026-08361-1.

 

[9] DailyMed. Norepinephrine Bitartrate Injection. 2026-04-16.

 

[10] U.S. Food and Drug Administration. Strattera (atomoxetine hydrochloride) capsules, prescribing information. 2022.

 

[11] U.S. Food and Drug Administration. Effexor XR (venlafaxine hydrochloride) extended-release capsules, prescribing information. 2017.

 

[12] MedlinePlus. Catecholamine Tests. 2024-08-21.

 

For more related articles, please see below:

 

Neurotransmitters, Receptors, and Transporters

 

The Key Molecule in Neurotransmission—Acetylcholine

 

Neurosteroids and Protective Mechanisms in the Central Nervous System

 

Nerve Growth Factor: Molecular Features, Signaling Mechanisms, and Key Technical Application Points

 

Central–Peripheral Signaling Networks Regulated by Neuropeptides and the Integration of Energy Metabolism